Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18243518 | 0.89 | SETD7 (0.36) | SETD7TP53CYP2D6CYP1A2DRD3 | |
| SCHEMBL18242409 | 0.85 | SETD7 (0.38) | SETD7TP53CYP2D6CYP1A2DRD3 | |
| SCHEMBL10419982 | 0.84 | SETD7 (0.40) | SETD7HTR2AKCNH2PTPN1 | |
| SCHEMBL9647956 | 0.83 | SETD7 (0.43) | SETD7HTR2AKCNH2PTPN1 | |
| SCHEMBL10760571 | 0.83 | SETD7 (0.43) | SETD7HTR2AKCNH2PTPN1 | |
| SCHEMBL6668478 | 0.78 | CALM1 (0.41) | CYP2D6CYP1A2TSHRADRA2CADRA1A | |
| SCHEMBL4787417 | 0.76 | GABRA1 (0.34) | TP53CYP2D6CYP1A2DRD3CHRM2 | |
| SCHEMBL4313202 | 0.76 | ALDH1A1 (0.37) | TP53CYP1A2ALDH1A1LMNAMAPT | |
| SCHEMBL6824881 | 0.73 | SETD7 (0.36) | SETD7TP53CYP2D6CYP1A2DRD3 | |
| SCHEMBL219752 | 0.72 | TSHR (0.36) | SETD7TP53CYP2D6CYP1A2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
| US-8252919-B2 | 2′-hydroxy-protected ribonucleoside derivative and production method thereof | KANEKA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | KANEKA CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258709-A1 | 2'-HYDROXYL-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND MANUFACTURING METHOD OF SAME | Kaneka Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20090275753-A1 | ORTHO-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG | NIPPON SODA CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| US-7569694-B2 | Coumarin compound, material for light emitting device and organic electroluminescent device | CHISSO CORPORATION (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1944024-A1 | O-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG | NIPPON SODA CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20070176544-A1 | Coumarin compound, material for light emitting device and organic electroluminescent device | JNC CORPORATION (JP) | 2007-08-02 | — | — | US | disclosed |
| US-5665885-A | FOR STABILIZING ORGANIC MATERIAL AGAINST THE DAMAGING INFLUENCE OF LIGHT, OXYGEN AND/OR HEAT | CIBA-GEIGY CORPORATION (US) | 1997-09-09 | — | — | US | disclosed |
| US-5637714-A | OXIDATION AND HEAT RESISTANCE; PHOTOSTABILITY | CIBA-GEIGY CORPORATION (US) | 1997-06-10 | — | — | US | disclosed |
| US-5510402-A | STABILIZING POLYOLEFINS AND STYRENE COPOLYMERS AGAINST HEAT, OXIDATION AND ACTINIC RADIATION | CIBA-GEIGY CORPORATION (US) | 1996-04-23 | — | — | US | disclosed |
| US-5457204-A | For polymers | CIBA-GEIGY CORPORATION (US) | 1995-10-10 | — | — | US | disclosed |
| EP-0634399-A1 | Adducts of hindered amine-epoxides as stabilisers | CIBA-GEIGY AG (CH) | 1995-01-18 | — | — | EP | disclosed |
| US-4713186-A | PHOSPHATE AND GRAPHITE OR INTERCALATION COMPOUND | LONZA LTD. (CH) | 1987-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | CBR1, HAO2, CBR3 | SETD7 3533/4885TP53 4315/4885CYP2D6 881/4885 |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | RNASEL, RNASEH1, NUDT1 | SETD7 1439/4885TP53 3962/4885CYP2D6 1550/4885 |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | CBR1, HAO2, CBR3 | SETD7 3533/4885TP53 4315/4885CYP2D6 881/4885 |
| US-20070176544-A1 | Coumarin compound, material for light emitting device and organic electroluminescent device | TRPA1, CYP3A4, UGT1A10 | SETD7 2423/4885TP53 4214/4885CYP2D6 76/4885 |
| US-20090275753-A1 | ORTHO-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG | NFE2L2, OXSR1, AOX1 | SETD7 1165/4885TP53 4164/4885CYP2D6 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.